#Merck

Very Low-Dose Weekly Islatravir Works as PrEP in Monkeys

FDA OKs Delstrigo and Pifeltro

United States of America map with state names

$7M HIV Initiative to Help Underserved People in the Southeast

Very Low-Dose Weekly Islatravir Works as PrEP in Monkeys

FDA OKs Delstrigo and Pifeltro

$7M HIV Initiative to Help Underserved People in the Southeast

Islatravir-Based Treatment Shows Promise

The HIV regimen failed only a few study participants.

islatravir

Deondre Moore promotes peer and community HIV education and prevention.

Ensuring Young, Black Communities Know the Transformative Message of U=U

AIDS United speaks with Deondre Moore about promoting U=U among African Americans via the “Owning HIV” campaign.

Yonce Jones of Harlem United will participate in the virtual panel discussion “HIV in Young, Black America.”

How Well Do Black Young Adults Understand HIV and U=U?

Survey findings from the “Owning HIV” campaign show the need for proactive education.

Treatment: Weekly Treatment?

MK-8507, a long-acting NNRTI, will be tested in a weekly regimen with islatravir.

Switching HIV Treatment to Delstrigo Is Safe and Effective

This is according to a three-year study in which people switched from a stable HIV regimen to Delstrigo.

Islatravir-Based HIV Regimen Fails Few Study Participants

None of the people who experienced virologic failure on regimens containing the experimental drug had a viral load of 200 or higher.

Islatravir Plus Pifeltro Shows Promise as 2-Drug HIV Regimen

A mid-stage trial showed the combo suppressed HIV, was well tolerated and resulted in a low rate of virologic failure.

Overcoming the Persistence of Stigma

Youth activists living with HIV are speaking truth to power.

What Do Gen Z and Millennials Think About HIV?

A new survey and educational campaign called “Owning HIV” offer insight.

Switching to New Tenofovir Linked to Rise in BMI and Cardiovascular Risk

This finding from a study of people switching from TDF to TAF for HIV treatment may also have implications for those on PrEP.

Islatravir Shows Double Potential

Merck’s experimental HIV drug proves effective and well tolerated

Pifeltro

The International AIDS Society Conference’s Most Vital Findings

A roundup of POZ’s reporting on studies presented at the Mexico City conference about HIV treatment, vaccines, PrEP and other concerns.

Merck’s Experimental HIV Drug Islatravir Proves Effective and Well Tolerated

This finding did not vary based on the dose of the nucleoside reverse transcriptase translocation inhibitor, formerly called MK-8591.

Long-Lasting Islatravir PrEP Implant Could Protect Against HIV for a Year

Early study shows implants delivers protective concentrations of a new antiretroviral for more than 12 months.

#Merck

Very Low-Dose Weekly Islatravir Works as PrEP in Monkeys

FDA OKs Delstrigo and Pifeltro

$7M HIV Initiative to Help Underserved People in the Southeast

Very Low-Dose Weekly Islatravir Works as PrEP in Monkeys

FDA OKs Delstrigo and Pifeltro

$7M HIV Initiative to Help Underserved People in the Southeast

Islatravir-Based Treatment Shows Promise

islatravir

Ensuring Young, Black Communities Know the Transformative Message of U=U

How Well Do Black Young Adults Understand HIV and U=U?

Treatment: Weekly Treatment?

Switching HIV Treatment to Delstrigo Is Safe and Effective

Islatravir-Based HIV Regimen Fails Few Study Participants

Islatravir Plus Pifeltro Shows Promise as 2-Drug HIV Regimen

Overcoming the Persistence of Stigma

What Do Gen Z and Millennials Think About HIV?

Switching to New Tenofovir Linked to Rise in BMI and Cardiovascular Risk

Islatravir Shows Double Potential

Pifeltro

The International AIDS Society Conference’s Most Vital Findings

Merck’s Experimental HIV Drug Islatravir Proves Effective and Well Tolerated

Long-Lasting Islatravir PrEP Implant Could Protect Against HIV for a Year

Treatment News

Features